PD-1 Inhibitor Treatment Effective for Localized   Mismatch Repair-Deficient CRC

FRIDAY, Jan. 13, 2023 -- For localized mismatch repair-deficient (dMMR) colorectal cancer (CRC), neoadjuvant programmed death-1 (PD-1) inhibitor treatment is effective, according to a study published online Jan. 11 in the Journal of the National...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news